Abstract| Volume 51, SUPPLEMENT 1, S8-S9, March 2015

Download started.


ITOC2 – 023. Integrated computational pipeline for development of personalised melanoma vaccine

      This paper is only available as a PDF. To read, Please Download here.


      Designing of immunotherapeutics, utilising patient derived dendritic cells generated hope for personalised melanoma vaccine. To provide sufficient immune signals, these dendritic cells are transfected with potential tumour associated antigens. Here we provide a computational pipeline to find the minimal set of epitopes based on patient haplotypes and patient specific mutation profile that help in simulating cytotoxic T cell mediated immunity.


      We identified over expressed proteins and proteins with validated melanoma associated mutations to predict novel tumour associated antigens. For our analysis, we considered MHC class-1 HLA allele frequency data from the German population eight ( For epitopes with known mutations in melanoma, we generated 3D structures and performed molecular docking and molecular dynamics simulation analysis to understand the impact of mutation on their binding affinity with HLA alleles and T-cell receptor.


      Using our computational analysis, we identified unique epitopes from proteins MCSP, MAGE-A3, Melan-A and survivin overexpressed in melanoma. We also used BRAF, NRAS, RAC1, KIT, STK19, MAP2K1 and CTNNB1 proteins with known mutations in case of melanoma.


      Our computational workflow is able to identify novel epitope sets with high confidence for experimental validations.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect